Ayala Pharmaceuticals (ADXS) Competitors $0.03 0.00 (-2.01%) As of 09:35 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock ADXS vs. BFRI, INDP, NLSP, SNGX, MTVA, ENSC, APLM, GTBP, FRTX, and ADILShould you be buying Ayala Pharmaceuticals stock or one of its competitors? The main competitors of Ayala Pharmaceuticals include Biofrontera (BFRI), Indaptus Therapeutics (INDP), NLS Pharmaceutics (NLSP), Soligenix (SNGX), MetaVia (MTVA), Ensysce Biosciences (ENSC), Apollomics (APLM), GT Biopharma (GTBP), Fresh Tracks Therapeutics (FRTX), and Adial Pharmaceuticals (ADIL). These companies are all part of the "pharmaceutical products" industry. Ayala Pharmaceuticals vs. Biofrontera Indaptus Therapeutics NLS Pharmaceutics Soligenix MetaVia Ensysce Biosciences Apollomics GT Biopharma Fresh Tracks Therapeutics Adial Pharmaceuticals Ayala Pharmaceuticals (NASDAQ:ADXS) and Biofrontera (NASDAQ:BFRI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations, earnings and community ranking. Is ADXS or BFRI more profitable? Ayala Pharmaceuticals has a net margin of 0.00% compared to Biofrontera's net margin of -36.31%. Ayala Pharmaceuticals' return on equity of 0.00% beat Biofrontera's return on equity.Company Net Margins Return on Equity Return on Assets Ayala PharmaceuticalsN/A N/A N/A Biofrontera -36.31%-565.73%-96.64% Does the MarketBeat Community believe in ADXS or BFRI? Biofrontera received 9 more outperform votes than Ayala Pharmaceuticals when rated by MarketBeat users. Likewise, 69.23% of users gave Biofrontera an outperform vote while only 0.00% of users gave Ayala Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAyala PharmaceuticalsOutperform VotesNo VotesUnderperform Votes87100.00% BiofronteraOutperform Votes969.23% Underperform Votes430.77% Do institutionals & insiders have more ownership in ADXS or BFRI? 7.2% of Ayala Pharmaceuticals shares are held by institutional investors. Comparatively, 10.1% of Biofrontera shares are held by institutional investors. 0.6% of Ayala Pharmaceuticals shares are held by company insiders. Comparatively, 1.2% of Biofrontera shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has higher earnings & valuation, ADXS or BFRI? Biofrontera has higher revenue and earnings than Ayala Pharmaceuticals. Biofrontera is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAyala Pharmaceuticals$3.24M0.46-$48.07M-$7.980.00Biofrontera$38.00M0.15-$20.13M-$2.26-0.27 Does the media favor ADXS or BFRI? In the previous week, Biofrontera had 2 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 2 mentions for Biofrontera and 0 mentions for Ayala Pharmaceuticals. Ayala Pharmaceuticals' average media sentiment score of 0.00 beat Biofrontera's score of -0.36 indicating that Ayala Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Ayala Pharmaceuticals Neutral Biofrontera Neutral Do analysts rate ADXS or BFRI? Biofrontera has a consensus price target of $2.75, suggesting a potential upside of 350.67%. Given Biofrontera's stronger consensus rating and higher probable upside, analysts plainly believe Biofrontera is more favorable than Ayala Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Biofrontera 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, ADXS or BFRI? Ayala Pharmaceuticals has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500. Comparatively, Biofrontera has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500. SummaryBiofrontera beats Ayala Pharmaceuticals on 11 of the 18 factors compared between the two stocks. Get Ayala Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADXS vs. The Competition Export to ExcelMetricAyala PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.49M$6.52B$5.38B$8.47BDividend YieldN/A2.64%5.28%4.17%P/E Ratio0.008.7326.9619.79Price / Sales0.46257.87413.22137.59Price / CashN/A65.8538.2534.64Price / Book-0.026.466.844.53Net Income-$48.07M$143.21M$3.22B$247.85M7 Day PerformanceN/A4.49%2.46%2.44%1 Month PerformanceN/A2.61%9.70%10.64%1 Year PerformanceN/A0.65%20.93%10.45% Ayala Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADXSAyala PharmaceuticalsN/A$0.03-2.0%N/A-86.8%$1.46M$3.24M0.0020Gap DownBFRIBiofrontera2.1697 of 5 stars$0.67+3.1%$2.75+310.5%-44.0%$6.33M$37.32M-0.3070Short Interest ↑Gap UpINDPIndaptus Therapeutics3.5998 of 5 stars$0.39-13.1%$8.50+2,079.5%-85.5%$6.25MN/A-0.236News CoveragePositive NewsShort Interest ↓Gap DownNLSPNLS PharmaceuticsN/A$1.71+5.8%N/A+1,248.3%$6.15MN/A0.006Short Interest ↓Gap DownSNGXSoligenix1.0769 of 5 stars$1.88+1.1%N/A-65.7%$6.14M$-117,029.00-0.2520MTVAMetaVia1.9935 of 5 stars$0.70+2.1%$7.50+973.0%N/A$6.05MN/A0.008Gap DownENSCEnsysce Biosciences0.1127 of 5 stars$2.55+9.0%N/A-76.0%$6.05M$2.23M-0.0910Short Interest ↑Gap DownAPLMApollomics0.3786 of 5 stars$5.40+10.4%N/A-79.1%$5.96M$1.22M0.0045Short Interest ↑Gap UpGTBPGT Biopharma3.5849 of 5 stars$2.24+0.4%$11.00+391.1%-21.8%$5.68MN/A-0.398Gap UpFRTXFresh Tracks TherapeuticsN/A$0.94-0.5%N/A+6.3%$5.59M$10.06M-0.6620ADILAdial Pharmaceuticals2.789 of 5 stars$0.70+6.4%$8.00+1,042.9%-42.7%$5.53MN/A-0.4820Short Interest ↑ Related Companies and Tools Related Companies Biofrontera Alternatives Indaptus Therapeutics Alternatives NLS Pharmaceutics Alternatives Soligenix Alternatives MetaVia Alternatives Ensysce Biosciences Alternatives Apollomics Alternatives GT Biopharma Alternatives Fresh Tracks Therapeutics Alternatives Adial Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADXS) was last updated on 5/30/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump Just Gave the Green Light to Rewrite Social Security?In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ayala Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ayala Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ADXS Stock Free ADXS Stock Alerts